UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 8, 2018

 

 AMPIO PHARMACEUTICALS, INC.  

(Exact name of registrant as specified in Charter)

 

 

 

Delaware   001-35182   26-0179592

(State or other jurisdiction of

incorporation or organization)

 

 

(Commission

File No.)

 

 

(IRS Employer

Identification No.)

 

373 Inverness Parkway, Suite 200

Englewood, Colorado 80112

(Address of principal executive offices, including zip code)

 

(720) 437-6500

(Registrant’s telephone number, including area code) 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 7.01 Other Events.

 

On January 8, 2018, Ampio Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company will be updating potential collaborators and attending shareholders at the J.P. Morgan Healthcare Conference. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K and a copy of the slide deck is being furnished as Exhibit 99.2 to this Report on Form 8-K.

 

The information in this Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

  Exhibit Number Description

 

99.1Press release issued by Ampio Pharmaceuticals, Inc., dated January 8, 2018, furnished hereto.

 

99.2Slide Deck, furnished hereto.

 

 

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       
  AMPIO PHARMACEUTICALS, INC.
     
  By:   /s/ Thomas E. Chilcott, III  
      Thomas E. Chilcott, III
      Chief Financial Officer

Dated: January 8, 2018

 

 

 

  

EXHIBIT INDEX

 

  Exhibit Number Description

 

99.1Press release issued by Ampio Pharmaceuticals, Inc., dated January 8, 2018, furnished hereto.

 

99.2Slide Deck, furnished hereto.